1422361-83-8

Basic information

• Product Name: 3-(3-bromopropoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
• Synonyms: 3-(3-bromopropoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide
• CAS NO: 1422361-83-8
• Molecular Weight: 470.098
• Mol File: 1422361-83-8.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 3-(3-bromopropoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-bromopropoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide(1422361-83-8)
• EPA Substance Registry System: 3-(3-bromopropoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide(1422361-83-8)

Safety Data

• Hazardous Substances Data: 1422361-83-8(Hazardous Substances Data)

Upstream product

• 1422361-81-6 3-(3-bromopropoxy)-4-(difluoromethoxy)benzaldehyde 
• 151103-08-1 4-difluoromethoxy-3-hydroxybenzaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 22889-78-7 3,5-dichloro-4-aminopyridine 
• 1422361-82-7 3-(3-bromopropoxy)-4-(difluoromethoxy)benzoic acid 

Downstream Products

• 1422361-69-0 N-{3-[4-{[(2,6-dichlorophenyl)amino]carbonyl}-2-(difluoromethoxy)phenoxy]propyl}homoserine 
• 1422361-70-3 2-[(3-{5-[(3,5-dichloropyridin-4-yl)carbamoyl]-2-(difluoromethoxy) phenoxy}propyl)amino]acetic acid 
• 1422361-50-9 N-(2,6-dichlorophenyl)-3-(difluoromethoxy)-4-{3-[(2-oxotetrahydrofuran-3-yl)amino]propoxy}benzamide 
• 1422361-49-6 C₂₀H₁₈Cl₂F₂N₂O₅S 
• 1422361-51-0 C₁₉H₁₉Cl₂F₂N₃O₅ 

Relevant articles and documents

Novel roflumilast analogs as soft PDE4 inhibitors

PDE4 inhibitors are of high interest for treatment of a wide range of inflammatory or autoimmune diseases. Their potential however has not yet been realized due to target-associated side effects, resulting in a low therapeutic window. We herein report the design, synthesis and evaluation of novel PDE4 inhibitors containing a γ-lactone structure. Such molecules are designed to undergo metabolic inactivation when entering circulation, thereby limiting systemic exposure and reducing the risk for side effects. The resulting inhibitors were highly active on both PDE4B1 and PDE4D2 and underwent rapid degradation in human plasma by paraoxonase 1. In contrast, their metabolites displayed markedly reduced permeability and/or on-target activity.